TMS Co., Ltd (4891)
Market cap
¥6.7B
P/E ratio
Timbs Inc. develops anti-inflammatory drugs from black mold compounds, targeting diseases like stroke and inflammatory conditions through partnerships with major pharmaceutical companies.
| Period End | EBITDA (Million JPY) | YoY (%) |
|---|